Company History

Marine Essence Biosciences is a high-tech company specializing in research and development of marine biotechnology. Through cutting-edge scientific innovations, ME-Bio harvests from unaltered marine ecosystems providing more advanced, safer and higher quality active ingredients, healthcare products and medical devices.

Marine biotechnology research has a huge potential to contribute to new knowledge for high value products and processes and increase marine resources and biodiversity understanding. After years of research and development supported by partnerships with renowned scientists, academics and researchers from top universities and institutes around the world, ME-Bio has completed various frontline technologies oriented to explore the potential of echinoderms as unique source of marine biotechnology products.


Our Vision

To become a world-leading company in healthcare and biomedical technology.


Our Mission

To dedicate ourselves to improving human wellness through our effort in discovering and developing innovative marine biotechnologies.

ME-Bio Scientific Partners

Scientific Partner 




Prof. Sergio M. Carballo

School of Chemistry, National University, Costa Rica (UNA)

University of Wisconsin-Madison

Former director of the School of Chemistry (UNA, Costa Rica) and the National Center for Biotechnological innovations (CENIBiot, Costa Rica). More than 20 years’ experience in biopolymers for applications in biomaterials, nanotechnology and medical devices. Currently works as Chief Scientist for ME-Bio.

Prof. William Fenical

Scripps Institution of Oceanography, University of California - San Diego (UCSD)

Director of SIO-Center for Marine Biotechnology and Biomedicine. Worldwide recognized expert in marine biotechnology.


Prof. David D’Argenio

Department of Biomedical Engineering, University of Southern California (USC)

Former Director of the Department of Biomedical Engineering. FDA’s expert in bioavailability studies and biosimilars.


Prof. Gerardo Rodriguez

School of Chemistry, National University, Costa Rica (UNA)

Former Director of the Laboratory of Phytochemistry (UNA, Costa Rica). More than 30 years’ experience natural products research, medicinal chemistry and development of nutritional supplements.


Angelica Ramos

California State University, Fullerton

Background in biology allowing support of regular analytical and quality control activities such as protein identification and quantitation, microplate reading experiments and collagen related bioassays. Strong background in cell and developmental biology, specially focused on stem-cell culture techniques, providing support in new biomaterials design and characterization by in vitro bioactivity assays.


M.Sc. Hilary Urena

Department of Biological Systems Engineering, University of Wisconsin-Madison

Bachelor degree in Biotechnology and Masters in Biological Systems Engineering, specializes in electrospinning techniques for manufacturing composite nanofiber biomaterials to be used in wound management applications by ME-Bio.


Christy Yau, B.Sc.

Graduated in Biochemistry at Simon Fraser University, where she also accumulated experience as a laboratory assistant specializing in Cell and Developmental Biology, Structural Biology, Nucleic Acid Function, and Immunology.  She has worked as a skin care consultant for a global leading company over the years, providing customers with innovative, effective skin care products. She is currently responsible for research and development, formulation and compounding for skin care products.

Our Technologies

Echinoderms are some of the most abundant multi-cellular animals in the marine world. It possesses unique connective tissues (Mutable Collagenous Tissues, MCT) which represents an innovative source of collagen and other by-products with unique properties and a huge scope of applications. Through our strategic scientific partnerships ME-Bio has completed several successful R&D projects which include production of high-purity echinoderm-derived collagen, a collagen-based cosmetic line for scar management and facial rejuvenation, echinoderm-based immune booster and prostate health supplements, and a wound management medical device, among others, some of which are ready to be manufactured in an industrial scale. The products have been submitted to rigorous quality control assays and are strictly in accordance with international standards to ensure consumer safety.

ME-Bio Chronology

  • June 2005

    Prior to establishing Marine Essence Biosciences, the company’s investors had begun their journey in searching for collagen materials and raw materials related to marine organisms in the marine field; as well as related research institutes and researchers with experience in the field.

  • Early 2010

    We started collecting the database of DNA and RNA extracted from the seabed of French Tahiti, Quebec, Canada, etc.; with approximately five years of data gathering; the company’s investors successfully completed the DNA and RNA database of the sea echinoderms at the end of 2015 and early 2016, respectively.

  • Therefore, when Marine Essence Bisociences was founded in 2017, researchers began their trial production of MCT collagen extracted from sea echinoderms for skin regeneration.

  • 2017

    Marine Essence Biosciences is founded.

  • April 2018

    ME-Bio starts a research agreement with Dr. Sergio M. Carballo (University of Wisconsin-Madison) for developing of guided tissue regeneration devices based on echinoderm collagen.

  • May 2018

    ME-Bio starts conversations with Prof. David D’Argenio (USC) to join the company as scientific advisor in the field of biomedical engineering.

  • June 2018

    ME-Bio inaugurates Marine Essence Biosciences Corporation of USA warehouse at Chino, CA, a biotech-focus facility equipped with state-of-the-art scientific instrumentation and automated production machines for supporting R&D and pilot production of cosmetics, supplements and medical devices.

  • July 2018

    ME-Bio started communications with FDA regarding future application to obtain FDA 510(k) clearance for our echinoderm collagen GTR medical device and successfully completed FDA 510(k) Pre-submission Q181250.

  • September 2018



  • ME-Bio receives the first positive review letter for FDA 510(k) pre-submission, indicating a pathway for successful approval of our GTR medical device.

  • October 2018

    Prof. Sergio M. Carballo (UW-Madison) is appointed as ME-Bio’s chief scientist, focusing on R&D projects to complete our collagen-based frontline technologies for guided tissue regeneration.

  • November 2018

    ME-Bio successfully completed FDA 510(k) extended pre-submission Q181250/S001.

  • December 2018

    ME-Bio signs a collaborative research agreement with Prof. Randall Loaiza for conducting cell culture experiments and preclinical trials in the field of echinoderm-derived cancer drug discovery at CENIBiot, Costa Rica. CENIBiot will also support ME-Bio in cell culture-based efficacy studies for wound management dressings.

  • January 2019

    ME-Bio starts a collaborative research agreement with Prof. Gerardo Rodriguez (UNA, Costa Rica) for the development of extraction protocols to isolate bioactive secondary metabolites from echinoderm for potential applications as new drugs and nutritional supplements.

  • ME-Bio received a positive review from FDA for extended pre-submission Q181250/S001 indicating the approval of our proposed preclinical trials for our GTR medical device.

  • February 2019

    ME-Bio successfully completed R&D projects in echinoderm collagen-based cosmetic product lines for scar management and facial rejuvenation.

  • March 2019

    ME-Bio signs a research agreement with Prof. William Fenical (UC-San Diego) for development of echinoderm-derived marine peptide supplements and drugs with potential applications for prostate cancer, and neurodegenerative diseases. The agreement involves funding of a Postdoctoral Fellow (Dr. Min Kim).

  • April 2019

    ME-Bio signs a research agreement with the Burn Unit at Xijing Hospital, and gets approval for conducting a standardized preclinical under FDA’s specifications in a porcine model for wound management.

  • May 2019

    ME-Bio files patent application No. 16/405,871 entitled: “MUTABLE COLLAGENOUS TISSUE FROM ECHINODERMS”.

  • ME-Bio successfully completed FDA 510(k) extended pre-submission Q181250/S002.

  • ME-Bio started conversations with Dr. Laila Elkeeb (UCI and Elkeeb MD Inc.) for designing clinical trials for our R&D projects on echinoderm collagen hydrogels loaded with stem cell for aesthetic applications.

  • June 2019

    ME-Bio files trademark application with USPTO for class 001, 003 and 005 mark for high-purity echinoderm collagen.

  • ME-Bio successfully completed stage one of its R&D project on composite electrospun nanofibers in collaboration with M.Sc. Hilary Urena at UW-Madison.

  • July 2019

    ME-Bio receives positive feedback from FDA 510(k) extended pre-submission Q181250/S002, indicating the final recommendations to successfully complete FDA 510(k) submission for our echinoderm collagen GTR medical device.

  • ME-Bio successfully completed several clinical efficacy trials on its echinoderm collagen-based cosmetic product lines for scar management and facial rejuvenation.

  • August 2019

    ME-Bio successfully completed two R&D projects in collaboration with Prof. Rodriguez (UNA, Costa Rica) for the manufacturing of echinoderm-based nutritional supplements for boosting immune system and promoting prostate health.

  • ME-Bio successfully completed cell culture efficacy trials (Stage 1) in its composite electrospun nanofiber dressing for potential treatment of diabetic feet in collaboration with Prof. Loaiza (CENIBiot, Costa Rica). After selection of optimized prototypes, we will proceed with preclinical trials (Stage 2).

  • September 2019

    ME-Bio successfully completed its second preclinical trial in collaboration with Xijin Hospital (Burn Unit) for evaluation of the wound management properties of ME-Bio’s echinoderm collagen GTR device against Integra® wound dressing (Integra Lifesciences) in a porcine model for second degree burns and partial thickness wounds.

  • ME-Bio successfully completed its frontline technology for cartilage regeneration, based on echinoderm collagen hydrogels with and without combination with stem cells.

  • October 2019

    ME-Bio works closely with UC-San Diego and Prof. Fenical in submitting a patent application for a recently discovered echinoderm marine neuropeptide.

  • ME-Bio successfully completed FDA 510(k) extended pre-submission Q181250/S003.

  • ME-Bio appointed Prof. David D’Argenio (USC) as scientific advisor for promoting scientific publication of ME-Bio’s completed frontline technologies.

  • ME-Bio signed an agreement with Prof. Manuel Estrada (Equine Hospital, Costa Rica) for the formulation, review and approval of our first preclinical trial in an equine model for cartilage regeneration.

  • November 2019

    ME-Bio will complete R&D and scaling up projects for manufacturing of echinoderm collagen-based luxury cosmetic line. ME-Bio will also complete submission of trademark application to USPTO on its luxury cosmetic mark name.

  • ME-Bio’s scientific advisor and chromatography expert (Prof. Gerardo Rodriguez) to join Prof. Fenical’s group at UC-San Diego as Visiting Professor for an extended collaborative research focused on drug discovery of novel triterpene glycosides from echinoderms with activity against gouty.

  • January 2020

    ME-Bio will start first preclinical (equine model) and clinical trials on its frontline technologies based on the combination of echinoderm collagen hydrogels and stem cells for cartilage regeneration and facial aesthetics, in collaboration with Prof. Estrada, DMV (Equine Hospital, Costa Rica) and Dr. Elkeeb, MD (UCI), respectively.

  • ME-Bio’s luxury cosmetic line based on echinoderm collagen will be ready for launching.